Cargando…
An expanded-access clinical study of thiotepa (DSP-1958) high-dose chemotherapy before autologous hematopoietic stem cell transplantation in patients with malignant lymphoma
Thiotepa, an antineoplastic ethylenimine alkylating agent that can penetrate the central nervous system, was recently approved in Japan as high-dose chemotherapy prior to autologous hematopoietic stem cell transplantation (HSCT) for patients with malignant lymphoma. To further evaluate the safety an...
Autores principales: | Nishikori, Momoko, Masaki, Yasufumi, Fujii, Nobuharu, Ikeda, Takashi, Takahara-Matsubara, Mariko, Sugimoto, Saori, Kondo, Eisei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619653/ https://www.ncbi.nlm.nih.gov/pubmed/34826108 http://dx.doi.org/10.1007/s12185-021-03263-y |
Ejemplares similares
-
Pharmacokinetics of thiotepa in high-dose regimens for autologous hematopoietic stem cell transplant in Japanese patients with pediatric tumors or adult lymphoma
por: Kondo, Eisei, et al.
Publicado: (2019) -
High-dose thiotepa, in conjunction with melphalan, followed by autologous hematopoietic stem cell transplantation in patients with pediatric solid tumors, including brain tumors
por: Hara, Junichi, et al.
Publicado: (2022) -
Correction: High-dose thiotepa, in conjunction with melphalan, followed by autologous hematopoietic stem cell transplantation in patients with pediatric solid tumors, including brain tumors
por: Hara, Junichi, et al.
Publicado: (2022) -
Phase 1/2 study evaluating the safety and efficacy of DSP‐7888 dosing emulsion in myelodysplastic syndromes
por: Ueda, Yasunori, et al.
Publicado: (2022) -
SS-4 High dose chemotherapy with autologous hematopoietic stem cell transplantation for CNS lymphoma
por: Kondo, Eisei
Publicado: (2020)